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Abstract
Background: Hepatitis C is a disease with significant global impact. According to the World Health Organization there are 71 million people chronically 
infected with the hepatitis C virus. About 399.000 people die each year, mostly from cirrhosis and hepatocarcinoma. GT 1 and 3 are the most common 
causes of infection. Chronic HCV infection is accompanied by extrahepatic manifestations reported in up to 75% of patients, rapid development of hepatic 
fibrosis and accelerated time to cirrhosis and increased risk for liver failure, HCC and liver-related mortality. HCV therapy is one of the interventions 
necessary to reduce global burden of disease. Because of their high virological efficacy, ease of use, safety and tolerability, IFN-free, ribavirin-free, DAA-based 
regimens must be used in HCV-infected patients without cirrhosis or with compensated cirrhosis, including: treatment-naive patients: never been treated 
for their HCV infection, treatment-experienced patients: previously treated with PEG-IFNa + RBV. From pangenotypic drugs or drug combinations for 
treatment HCV in Europe are recommended: sofosbuvir/velpatasvir, sofosbuvir/velpatasvir/voxilaprevir and glecaprevir/pibrentasvir. Genotype-specific 
drugs sofosbuvir/ledipasvir, ombitasvir/paritaprevir/ritonavir, or grazoprevir /elbasvir are recommended for (GT 1, 4, 5 and 6).
Conclusions: The new direct-acting antiviral treatment regimens can be given to most patients with chronic hepatitis C virus infection, including those 
with liver cirrhosis, they have shown high efficacy, achieving sustained virologic response in over 90% of patients. DAA are well tolerated and have 
minimal side effects that do not require treatment discontinuation.
Key words: viral hepatitis C, direct-acting antiviral combination therapies.
ReVIeW ARTIcLe
Introduction
Prior to the identification of HCV, only a small number 
of Non-A Non-B hepatitis patients have been successfully 
treated by long-term administration of interferon-alpha. 
However, the molecular features of hepatitis C virus made 
it possible to develop specific treatment and laboratory tests 
for the diagnosis and monitoring of HCV infection [1].
According to WHO data, around 70 million people with 
HCV infection were estimated by the end of 2017 viz. ap-
proximately 2-2.5% of the world’s total population [2]. In 
the republic of Moldova, the incidence rate makes up 4.5% 
of people aged 30-49 and more prevalent in males than in 
females [3]. According to the National Public Health Agen-
cy data, the analysis of the dynamics of viral hepatitis mor-
bidity over the last 10 years shows a continuous increase in 
cases of chronic hepatitis and liver cirrhosis in the Republic 
of Moldova. The prevalence of chronic HCV tends to in-
crease from 189.4 in 2008 to 441.5 cases per 100.000 per-
sons in 2017. This tendency of HCV morbidity growth is 
due to the lack of specific HCV preventive measures, as well 
as high level of viral hepatitis detection. It also should be 
noted that liver cirrhosis mortality, including hepatitis C vi-
rus has decreased from 88.3 to 100 thousand individuals in 
2009 to 62.7 per 100 thousand population in 2017 as a result 
of the National Program for Combating Hepatitis B, C and 
Delta viruses [4, 5]. Chronic hepatitis C virus infection is 
one of the most common causes of chronic liver disease and 
liver transplantation all over Europe and the US. It is diffi-
cult to determine the number of new HCV infections since 
the most acute cases have not been clinically identified. Less 
than 25% of acute HCV cases are detected based on clinical 
manifestations [6].
Antiviral therapy: historical background,  
objectives and adverse reactions to treatment
Prior to of HCV identification, interferon-alpha was 
considered as a potential therapy in non-A, non-B viral 
hepatitis, which contributed to both normalization of trans-
aminases and improvement of liver histology in some pa-
tients [1]. Since the identification of HCV by Choo in 1989, 
it has become possible to quantitatively determine the level 
of serum HCV RNA and evaluate the effectiveness of long-
term viz. obtaining a sustained virologic response (SVR). 
The first studies showed that Interferon-alpha-2b 3MU 
administered 3 times / week for 6 months has achieved SVR 
in 8% of cases, and increased to only 12% when therapy 
continued up to 12 months [7, 8].
Ribavirin alone was used in the treatment of chronic 
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HCV for the first time in 1991. Ten patients were adminis-
tered Ribavirin 1000-1200 mg / day for 12 weeks. There was 
a considerable decrease in transaminases during treatment, 
however these returned to initial level after drug withdraw-
al. Hepatitis C virus has not been completely removed in 
any of the patients [9]. An increase in the effectiveness of 
antiviral treatment was observed in combined therapy viz. 
Ribavirin and IFN-alpha. Two major randomized trials were 
conducted in order to compare the efficacy of combined 
IFN-alpha-2b + Ribavirin and Interferon-alpha-2b alone 
administered to naive patients. The first results established a 
sustained virological response in 47-50% of cases following 
a combined therapy, whereas only 13% patients with Inter-
feron alone and 0% in patients with Ribavirin monotherapy 
[10, 11]. The synthesis of pegylated interferon (PEG-IFN) 
that contains pegylated proteins and shows a much longer 
half-life, has improved the pharmacokinetics of IFN, thus 
reducing the dosing intervals. Two types of IFN-PEG are 
currently available: PEG-IFNα-2b (PEG-Intron, Merck) 
and PEG-IFNα-2α (PEGASYS, Roche). A large multicenter 
study in the US has not established any significant difference 
between the two PEG-IFN and RBV regarding SVR [12].
The combined therapy of PEG-IFN α-2a (180 μg / kg / 
week) and RBV at a dose of 1000 mg was found to be ef-
fective if the body weight <75 kg or 1200 mg if the body 
weight ≥75 kg in patients with GT1 HCV [13]. In case the 
hemoglobin level drops below 10 g / dl, the dose of ribavirin 
should be reduced by 200 mg and discontinued if the hemo-
globin level is below 8.5 g / dl [14, 15]. Several studies were 
conducted on chronic HVC patients following a PEG-IFN + 
RBV treatment during the period of 2011-2013 years.  SVR 
was reported in 42-52% of GT1 patients within 48 weeks 
and 76-84 % of GT2 and GT3 individuals within 24 weeks 
[16, 17]. Treatment regimens with PEG-IFN-α and Ribavi-
rin are still valid for countries with limited access to DAA.
A good treatment adherence is an important factor in 
achieving optimal outcomes in the antiviral treatment of 
chronic hepatitis C virus infection. Adherence to interfe-
ron and ribavirin treatment was particularly difficult, since 
these have been the only option available over the past two 
decades. Almost all patients treated with interferon and 
ribavirin exhibited adverse reactions that significantly in-
fluenced the treatment adherence. The most common side 
effects were reported in patients treated with pegylated in-
terferon and ribavirin showing symptoms of general intoxi-
cation and asthenia – 66%, headache – 50%, nausea – 43%, 
insomnia – 39%, pyrexia – 35%, anemia(10 g / dl) – 34%, 
myalgia – 27%, neutropenia (<1000 cells / μl) – 26%, de-
pression – 26%, irritability – 25% and rash – 22%. Accor-
ding to Seyam et al. [18], 6-10% of patients who adminis-
tered interferon therapy for 48 weeks lost weight. Weight 
regained quickly after therapy discontinuation.
The most frequent psychiatric adverse events induced 
by IFN α include fatigue – 40-80%, sleep disturbances – 
20-45%, irritability – 20-45%, cognitive disorders affect-
ing concentration and memory – 20-30 %, depressive epi-
sodes – 20-70%, delirium, psychosis, mania – 1-3%, suicidal 
thoughts – 3-10%, and suicide attempts – 0-0.02% of in-
dividuals [19, 20]. Interferon therapy is accompanied by a 
30-50% decrease in the absolute number of WBCs within 
the first 4-8 weeks from the treatment onset and a rapid in-
crease after its withdrawal. Anemia (<10 g/dl) was reported 
in up to 20% of patients [13]. The dose of ribavirin should 
have been reduced in severe cases of anemia. Thrombocyto-
penia occurs within the first 2 months after the onset of IFN 
therapy, reducing the platelet count by 30-40% compared 
to values before the treatment. As a rule, the platelet count 
returns to its normal values after 4 weeks from the antiviral 
therapy withdrawal [21]. Combination of Boceprevir and 
Telaprevir protease inhibitors in the treatment of chronic 
HCV increased the SVR rate up to 75% in HBV naïve pa-
tients [22, 23] and up to 29-88% in patients pretreated with 
antiviral drugs [24, 25]. However, both protease inhibitors 
required combination with PEG-IFN and Ribavirin, since 
the monotherapy may develop a rapid resistance and severe 
side effects such as anemia.
A French cohort study was conducted on patients with 
compensated liver cirrhosis who underwent telaprevir or 
boceprevir regimen. Severe adverse reactions (anemia in up 
to 50% of patients), including sepsis, hepatic decompensa-
tion and even death were reported [26, 27]. Renal failure 
was registered in patients following a triple therapy with 
telaprevir and bocepravir. Impaired renal function was re-
ported in patients with pre-existing risk factors for renal 
disorders associated with a more marked decrease in he-
moglobin level that was reversible in most cases after the 
treatment withdrawal [28, 29]. Due to a wide range of side 
effects of interferon, telaprevir and boceprevir-based triple 
therapy, their production was discontinued after approval of 
interferon-free treatment with DAA.
Sofosbuvir, the first polymerase inhibitor, has substan-
tially improved the therapeutic efficacy in patients with 
chronic HCV. Treatment with PEG-IFN / RBV and SOF for 
a period of 12 weeks showed 89% SVR rate. When admi-
nistered in combination with interferon and ribavirin, it ex-
hibited minor adverse effects and a limited drug interaction 
[30, 31].
However, due to its renal excretion, Sofosbuvir should 
cautiously be administered in patients with advanced kid-
ney disease and glomerular filtration rate <30 ml / min, 
as well as in end-stage renal diseases, unless an alternative 
treatment is available.
Interferon-free antiviral treatment: indications,  
contraindications, new treatment regimens with  
direct-acting antivirals
As new therapeutic opportunities have emerged, each 
patient with confirmed chronic hepatitis C should receive 
antiviral treatment. Patients who undergo a HCV infection 
treatment may experience a higher quality of life and a low-
er risk of developing liver cirrhosis, hepatocellular carcino-
ma and mortality associated with hepatic and extrahepatic 
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pathology [32, 33]. According to EASL 2018 recommenda-
tions, patients with chronic HCV should be preferably ad-
ministered direct-acting antivirals with IFN-free and RBV-
free regimens. The treatment should be initiated as soon as 
possible in patients with advanced fibrosis and an increased 
risk of liver complications. Moreover, a priority for imme-
diate treatment of patients with hepatitis C virus is the se-
verity of extrahepatic manifestations. Another reason for an 
early initiation of treatment in all individuals diseased with 
HCV infection is its further prevention and transmission to 
people at high risk (intravenous drug users, men who have 
sex with men, women in childbearing age, hemodialysis pa-
tients, inmates in prisons) [15].
Antiviral treatment is not recommended in patients with 
short-life expectancy due to non-HVC comorbidities [15].
The predictive factors for the selected treatment regimen 
should be considered prior to initiating the antiviral therapy 
in order to increase the SVR rate. Even though, HCV gen-
otype, liver fibrosis and steatosis, initial viral load, insulin 
resistance, age, gender, BMI, ethnicity, and HIV co-infec-
tion are the SVR predictive factors suggesting the initiation 
of PEG-IFN / RBV therapy, then most of these factors are 
much less important for DAA therapy. The HCV genotypes 
1a and 1b, antiviral resistance and in most countries the 
treatment cost are the other important parameters for IFN-
free therapy. However, the severity of the disease at time 
of treatment initiation is still important to assess [34, 12]. 
Although there is a number of available antiviral regimens, 
not all of them show a pangenotypic effect, thus genotyp-
ing is mandatory when initiating an antiviral treatment in 
order to select the optimal regimen and treatment duration 
of chronic HCV [35]. 
If the HCV RNA level has been and remains the most 
important predictive factor of SVR in PEG-IFN + RBV 
treatment, at present, when new DAA regimens have been 
used, the HCV load does not appear to have a significant 
predictive value. Concomitantly, according to 2018 EASL 
recommendations, RNA-HCV concentration (<600.000-
800.000 IU/ml) is a condition for reducing treatment dura-
tion in naive non-cirrhotic patients who initiate IFN-free 
treatment with sofosbuvir and ledipasvir [36, 37].
According to 2018 EASL guidelines, the viral load as-
sessment is recommended only prior to treatment and at 
12 or 24 weeks after the antiviral therapy ceases. Instead of 
HCV RNA, the HCV core antigen may be performed if HCV 
RNA tests are not available [15].  At the same time, quanti-
tative HCV-RNA testing is recommended by the AASLD/
IDSA guidance on week 4 of DAA therapy to monitor the 
patient compliance [48].
Interleukin IL28B plays an important role as a predic-
tive factor for SVR in PEG-INF / RBV / IP treatment. IL28B 
has a much greater significance than the HCV load. IL28B-
related data explain the SVR difference in PEG-INF / RBV 
treatment among different ethnic groups, such as reduced 
SVR in African and American patients, and a high SVR in 
Asian patients. Female gender, initial viremia of <6 log10 
IU/ml and body mass <30 kg/m2 are additional factors that 
may influence the SVR in SOF / LDV therapy. Patients with 
HCV GT1b respond better to some approved DAA thera-
pies. The stages of liver damage and previous experience 
with PEG-IFN + RBV are important predictors in treatment 
response [38].
The emergence of DAA therapies has given rise to an-
other major problem viz. developing drug-resistance. Pa-
tients receiving first-generation HCV-protease inhibitors 
boceprevir and telaprevir developed resistance within a few 
days. If resistance develops, it is not known yet how long it 
will persist and what are the significant consequences for 
future therapies. Some studies suggest that most IP-resistant 
variants revert to wild type within 1-2 years after the com-
pletion of treatment [39].
The combination of different DAA classes might solve 
out the problem of resistance. SOF has a very high resis-
tance barrier [40]. Combined SOF and NS5A inhibitor (SOF 
/ DCV or SOF / LDV or SOF / VEL) exhibit a SVR > 90%. 
However, according to the studies, NS5A-associated resis-
tance may become a problem within the clinical practice.
Several studies on initial resistance prior to treatment 
initiation with NS5A inhibitors have been performed. The 
resistance made up approximately 16% in SOF / LDV group 
[39] and 20% in the GZR / EBR-treated patients [41]. The 
resistance levels have no impact on SVR in HCV GT1b 
patients, though it may be significant in GT1a and GT3 
cases, particularly if other negative predictors (previous 
non-responder or advanced cirrhosis) are present. For these 
reasons, there is no point in assessing the resistance level 
prior to treatment initiation via first-line preparations; this 
should be done when selecting the optimal therapy unless 
the combined DAA therapy has failed.
Interferon-free direct-acting antiviral therapy has be-
come available in many countries since 2014 and has substi-
tuted the standard interferon therapy. DAAs have shown a 
much better efficacy, a substantially improved tolerance and 
shorter treatment duration compared to interferon therapy 
[42, 15].
The DAA groups are as following NS3 / 4A protease 
inhibitors, NS5B polymerase inhibitors and NS5A replica-
tion complex inhibitors. The combination of at least two of 
these three major drug classes results in ≥95% of SVR in just 
8-12 weeks of treatment [42]. Treatment options are differ-
ent across the world, as not all countries have access to new 
treatment regimens, whereas the generic preparations [43] 
are available in few countries. 
Since 2016, in the Republic of Moldova, the National 
Treatment Program of Viral Hepatitis has developed a pro-
gram on antiviral treatment with DAAs of chronic HVC 
that has become available now. Two regimens were ap-
proved: sofosbuvir + ledipasvir and sofosbuvir + daclatasvir.
Sofosbuvir (SOF) is an all-genotype NS5B polymerase 
inhibitor with high resistance barrier that is combined with 
other antivirals. Sofosbuvir alone is not allowed. The com-
bination of sofosbuvir with NS5A-daclatasvir (DCV) or le-
dipasvir (LDV) inhibitors has reached SVR in over 90% of 
cases [38, 44].
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The SOF + LDV treatment regimen is available in a 
single tablet containing SOF (400 mg) and LDV (90 mg). 
This once-daily taken preparation is an advantage since it 
improves the treatment adherence. According to the EASL 
2018 guide, SOF / LDV is recommended for patients infect-
ed with genotype 1, 4, 5 and 6 and is not recommended for 
patients with genotype 2 and 3. It should be used with cau-
tion in patients with chronic kidney disease where GFR <30 
ml / min, unless other recommended therapeutic regimens 
are available and can be used without restrictions in patients 
with decompensated cirrhosis.
In patients GT1 chronic HCV-infected patients without 
cirrhosis, the treatment with SOF/LDV for 12 weeks reached 
a SVR of 96%, while treatment for 24 weeks – in 99% cases.
Most studies conducted in naive patients with HVC GT 
2 and 3 [45] and  treated with SOF/LDV experienced re-
duced SVR rates (64-68%), and those who received SOF/
LDV regimen + RBV result in SVR of 97 – 100%. Based on 
these results, the SOF/LDV treatment regimen is not rec-
ommended in patients with HVC GT 2 and 3 because there 
are more optimal treatment options.
Based on study analysis of patients with GT4, 5 and 6 
there is little data on IFN-free regimens. A study conducted 
on 41 naïve patients with GT5 and 25 with GT6 for 12 weeks 
with SOF / LDV, SVR resulted in 95-96% [45, 46].
HCV genotyping is required in order to select the best 
Direct-Acting Antiviral regimen. However, there are pa-
tients in whom genotyping was not possible to determine or 
mixed genotypes were recorded. In this case, AAD pangeno-
typic regimens are available. Combination of sofosbuvir and 
daclatasvir (DCV) is an example of such a regimen.  Dacla-
tasvir is an inhibitor of the NS5A replication complex and is 
given once daily at a standard dose of 60 mg [47].
The results of several studies confirmed that treatment 
with SOF / DCV and RBV-free for 12 weeks is recom-
mended for naïve patients without cirrhosis. Treatment of 
cirrhotic patients should last up to 24 weeks. The treatment 
might be reduced up to 12 weeks in patients with cirrhosis, 
previously untreated and showing positive prognostic fac-
tors [38, 44].
A study was conducted on 41 patients with non-cirrhotic 
HVC GT1 who underwent PEG-IFN + RBV + IP and dem-
onstrated a 100% SVR in both SOF + DCV therapy for 24 
weeks and in SOF + DCV + RBV regimen for 24 weeks [44]. 
Since 2018, Daclatasvir has not longer been used in a series 
of countries, such as Germany, because it has to be com-
bined with sofosbuvir, and this treatment regimen is more 
costly than any other pangenotypic AAD recommended in 
the 2018 EASL guide. However, the combination of sofosbu-
vir and daclatasvir is the basic treatment in countries where 
the generic drugs are used.
Among the pangenotypic combinations approved in 
2017, the association of Glecaprevir – NS3 / 4A protease in-
hibitor and Pibrentasvir that is the second-generation selec-
tive inhibitor of the NS5A replication complex (GLE / PIB) 
is also possible. An integrated analysis of all Phase 2 and 3 
studies in cirrhotic and non-cirrhotic patients showed very 
good results within a 12-week GLE / PID treatment, thus 
SVR was established in 99.8% of patients with GT1, 99% 
in patients with GT2, 95% in GT3, 99-100% in GT4-GT6 
patients. There were no statistically significant differences in 
naive and pre-treated patients. The SVR rate was quite high 
within the group of  patients treated for 8 weeks and ranged 
from 99% in GT1 and GT2 up to 92% in GT6 [48]. Based 
on these study results, an 8-week treatment with GLE / GDP 
is recommended for naive, non-cirrhotic patients and 12 
weeks for naive patients with cirrhosis. 
A 16-week GLE / PIB treatment [15, 49] is recom-
mended in cirrhotic and non-cirrhotic patients treated with 
AADs.  Another pangenotypic regimen includes sofosbu-
vir (SOF) and velpatasvir (VEL) that are available in a fixed 
dose of 400 / 100mg SOF / VEL in one tablet. According to 
the results of the Phase 3 trials, the standard treatment for 
12 weeks in all chronic HCV patients, GT1, 2,4,5,6 and non-
cirrhotic CT3 patients has recorded SVR in 97-100% and 
there was no obvious difference between experienced and 
naive patients [50, 51, 52]. A complete analysis of patients 
with advanced fibrosis and cirrhosis demonstrated SVR in 
98% and 99%, respectively. Therefore, this therapeutic regi-
men may be recommended for all HCV patients, regardless 
of the stage of fibrosis, including those experienced, how-
ever  not recommended for patients with chronic kidney 
disease (GFR <30 ml / min) [52, 53].
Nevertheless, the new DAA treatment regimens show 
very good results in the treatment of chronic HCV, there 
were subjects who did not achieve SVR. The combination of 
sofosbuvir, velpatasvir and voxilaprevir (VOX), approved in 
2017, should be used as an alternative regimen for the treat-
ment of patients who failed to respond to NS5A inhibitor 
therapy. This treatment has a pangenotypic effect and can 
be used as a first-line treatment regimen [54]. Two studies 
of Phase 3 investigated SOF / VEL / VOX treatment in both 
naïve and DAA patients.SVR recorded 96-100% of patients 
infected with all HCV genotypes, with or without cirrhosis 
[55]. Antiviral treatment exhibits some adverse effects, as 
well.  Once the new DAA interferon-/ribavirin-free regi-
mens have been introduced, the rate of adverse effects has 
decreased substantially, thus most patients complain of mi-
nor manifestations such as fatigue, headache, insomnia and 
nausea [56]. These side effects do not require discontinua-
tion of treatment. 
Patients treated with ribavirin, in addition to anemia, 
may experience pruritus, dry skin, coughing, and dyspnoea 
[57]. These side effects have already been described in com-
bined ribavirin and interferon regimen but their incidence 
and severity are lower when ribavirin is combined with di-
rect-acting antivirals. However, there have been a number 
of severe complications as bradycardia and cardiac arrest, 
including some lethal outcomes in patients taking antiar-
rhythmic drugs, particularly amiodarone, in combination 
with DAA including sofosbuvir [58].
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Conclusions
1. Hepatitis C virus (HCV)-related morbidity is a major 
current issue both worldwide and in the Republic of Mol-
dova. This disease predominantly affects persons aged 30-49 
years, and tends to develop into hepatic cirrhosis and hepa-
tocellular carcinoma.
2. Lack of specific HCV prophylaxis requires the iden-
tification of cases of HCV infection and the application of 
effective treatment regimens.
3. Over the last two decades, the only available treat-
ment option for chronic HCV was PEG-IFN and RBV for 
48 weeks, which recorded a 42-52% SVR in patients with 
GT1 and for 24 weeks – 76-84% in those with GT2 and GT3. 
However, the treatment was accompanied by a series of side 
effects in over 50% of patients, which reduced adherence to 
therapy.
4. The new direct-acting antiviral treatment regimens 
can be administered in most patients with HCV infection, 
including those with liver cirrhosis. These proved to be 
highly effective, resulting in a sustained virologic response 
in over 90% of patients.
5. DAAs are well tolerated and have minimal side effects 
that do not require treatment discontinuation.
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